Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would really like to see data from the trial on the impact of Brilacidin on viral load levels throughout the trial. If Covid levels are significantly decreased by B treatment compared to SOC, that would be very significant. Such data could bring in funds/joint venture to support a prophylactic treatment, as mentioned by Leo.
Agree, big overreaction. expected, IMO. Would love to hear a communication from Leo on future trials, next deveopment steps, etc. Awaiting breakdown of the trial data....Would love to see a BP come in and by all assets!
Cold Spring Harbor may be the most prestigious molecular biology research laboratories in the world. They literally wrote the book on genetic engineering years back.... That is a great finding to identify and prove this additional mechanism of action for B. Very impressive!
I'm sorry, I must have missed it. Please define what "TLD" stands for?
Thanks!
that might explain it....
Just to add,
https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1250916
Conclusion:
rNHC showed a dose-dependent inhibition and mutagenic effect of SAR-CoV-2 in vitro. However, rNHC would be expected to be metabolized into the deoxynucleotide pool (by host RNR), resulting in DNA mutation of dividing mammalian cells. We demonstrated such mutagenic potential in a simple mammalian cell detection scheme. Molnupiravir has considerable potential as an orally bioavailable direct acting antiviral against SARS-CoV2 early in infection, especially in high risk patients. However, clinical use should be carefully considered in light of its potential mutagenic effects on the host.
Brilacidin nasal spray. I would love to see IPIX delelop a nasal spray to irradicate the virus in the nasal mucosa of folks who have been vaccinated...Apparently vaccination irradicates the visus in the lungs and systemically, but not in the nasal mucosa....thus those infected yet vaccinated can still spread the virus....Long!
Misinformation hurts us all. Denying scientific rationale hurts us all. Propagation of lies hurts us all. I agree B can be a huge medicine fighting Covid and other ailments, but the lies spread by certain media leading to vaccine hesitancy hurt us all. Farrell90 posted an excellent article, which is worth reading by all.
https://www.newsweek.com/2021/08/13/doomsday-covid-variant-worse-delta-lambda-may-coming-scientists-say-1615874.html
Mike Lindell advertizing on the page...sure, must be believable...
Just added :)
Antibodies have limited utility against variants - Brilacidin to the rescue!
https://www.cnn.com/2021/03/26/health/us-coronavirus-friday/index.html
That is an excellent idea, IMO,. An extended release tablet may give someone longer term protection if exposed to a risky environment. We need the positive IV results first! :)
Any word of tthe development of a tablet formulation of Brilacidin specific for antiviral use....? Prophylactic use if exposed to COVID...possiblyl an extended release formulation?
Just about allof those points are dangerously inaccurate and spreading these falsifications harms so many...
I just added...
Questioning the validity of the peer reviewed article....Wow, that is rich!
Of Major interest to IPIX and Leo!
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap
FDA has created a special emergency program for possible coronavirus therapies, the Coronavirus Treatment Acceleration Program (CTAP). The program uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness.
For Researchers and Developers of Therapeutics
FDA is accelerating the development and publication of guidances and other information for industry on developing COVID-19-related treatments. Key references include:
Dr. Jerry,
Charles Triano is in Public Relations. Maybe send the email to Albert Bourla (CEO)
S
Long time IPIX holder, very happy to see this!
Another application for B would be impregnation of fibers on facemasks...
coat surfaces touched in public places with a B polymer ...
OK, novel idea? Impregnate face masks with B... impregnate AC air filters with B...Hospital surfaces....
Polymedix talked about this years ago..
Its not fully clear what anti-inflammatory activity will be tested, although this sentence, "VEEV has been chosen as a prototype because of the RBL’s focus in this area, possessing in-house necessary assays to assess the antiviral and anti-inflammatory activity of a given compound. Brilacidin also will be compared with other small molecules to assess Brilacidin’s potential relative efficacy." does mention an assessment of this....
Folks, Does anyone know know who/what testing of B as a therapeutic agent (not antivral) will be performed? I would think its ant-inflammatory activity would be investigated as well (inhalation, etc)
Yes, that makes total sense. I could not find any literature supporting antiviral activity , but maybe there is some evidence not in the public of anti viral activity....but anti-inflammatory, makes total sense! Also secondary infections (pneumonia, etc.) are a problem, which could be treated by B.
I would guess that the questions posed by Nerby (excellent points) regarding the stability of B in the sachet, mixing with tap water, etc, would be part of the EOP2 mtg discussion regarding what data are required to be included in the NDA. What is to be included in the the planned NDA is typically the core of the discussions in the EOP2 mtg.
Possibly a candidate for an extended release one/day formulation...
A 505(b)2 can be used to reference the safety information in the Ziagen (abacavir) application, which in this case is fully applicable here. FDA agreed on this.
As the lawsuit is on behalf of shareholders that have lost $$, I think Rosen and Co should be going after SA and Mako for causing shareholder losses by disseminating blatantly false information with the intent of driving the share price lower. Certainly would be a much stronger case!